Morgan Stanley's note on 
CRM: Weak bookings in Q1 further test investor patience as the GenAI innovation cycle has yet to inflect top-line results and now increasingly becomes a point of competitive concern. However, the multiple does not reflect any GenAI expectations and actually under prices core EPS growth.
CRM: Weak bookings in Q1 further test investor patience as the GenAI innovation cycle has yet to inflect top-line results and now increasingly becomes a point of competitive concern. However, the multiple does not reflect any GenAI expectations and actually under prices core EPS growth.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.